BioCryst Pharmaceuticals, Inc. (BCRX) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
BCRX Insider Trading Activity
BCRX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $191,646 | 4 | 50 |
Sells | $176,191 | 4 | 50 |
Related Transactions
| MILANO VINCENT | director | 1 | $93,750 | 0 | $0 | $93,750 |
| LEVIN ALAN G | director | 1 | $49,996 | 0 | $0 | $49,996 |
| Hutson Nancy J | director | 1 | $31,900 | 1 | $52,780 | $-20,880 |
| ASELAGE STEVE | director | 1 | $16,000 | 0 | $0 | $16,000 |
| SANDERS MACHELLE | director | 0 | $0 | 1 | $28,134 | $-28,134 |
| HEGGIE THERESA | director | 0 | $0 | 1 | $40,925 | $-40,925 |
| McKee Amy E | director | 0 | $0 | 1 | $54,352 | $-54,352 |
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Insider Activity of BioCryst Pharmaceuticals, Inc.
Over the last 12 months, insiders at BioCryst Pharmaceuticals, Inc. have bought $191,646 and sold $176,191 worth of BioCryst Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at BioCryst Pharmaceuticals, Inc. have bought $505,106 and sold $4.18M worth of stock each year.
Highest buying activity among insiders over the last 12 months: MILANO VINCENT (director) — $93,750. LEVIN ALAN G (director) — $49,996. Hutson Nancy J (director) — $31,900.
The last purchase of 7,861 shares for transaction amount of $49,996 was made by LEVIN ALAN G (director) on 2024‑05‑30.
List of Insider Buy and Sell Transactions, BioCryst Pharmaceuticals, Inc.
| 2024-12-13 | Sale | Hutson Nancy J | director | 7,000 0.0034% | $7.54 | $52,780 | +4.18% | |
| 2024-06-24 | Sale | McKee Amy E | director | 8,600 0.0042% | $6.32 | $54,352 | +22.65% | |
| 2024-06-17 | Sale | SANDERS MACHELLE | director | 4,689 0.0021% | $6.00 | $28,134 | +22.92% | |
| 2024-06-14 | Sale | HEGGIE THERESA | director | 6,698 0.0031% | $6.11 | $40,925 | +24.31% | |
| 2024-05-30 | LEVIN ALAN G | director | 7,861 0.0037% | $6.36 | $49,996 | +16.29% | ||
| 2024-05-24 | ASELAGE STEVE | director | 2,500 0.0012% | $6.40 | $16,000 | +24.55% | ||
| 2024-05-20 | Hutson Nancy J | director | 5,000 0.0025% | $6.38 | $31,900 | +24.47% | ||
| 2024-05-20 | MILANO VINCENT | director | 15,000 0.0074% | $6.25 | $93,750 | +24.47% | ||
| 2024-05-14 | Thackray Helen M. | Chief R&D Officer | 30,000 0.0159% | $5.86 | $175,800 | +42.26% | ||
| 2024-05-14 | Doyle Anthony | Chief Financial Officer | 36,300 0.0183% | $5.57 | $202,191 | +42.26% | ||
| 2024-05-13 | Stonehouse Jon P | President & CEO | 30,000 0.0143% | $5.55 | $166,500 | +35.35% | ||
| 2024-05-13 | Gayer Charles K | Chief Commercial Officer | 30,000 0.0141% | $5.47 | $164,100 | +35.35% | ||
| 2024-05-13 | Barnes Alane P | Chief Legal Officer | 5,000 0.0024% | $5.53 | $27,650 | +35.35% | ||
| 2024-05-13 | Galson Steven K | director | 21,940 0.0104% | $5.49 | $120,451 | +35.35% | ||
| 2023-06-15 | Sale | SANDERS MACHELLE | director | 4,000 0.0021% | $7.98 | $31,920 | -24.81% | |
| 2023-06-14 | Sale | Hutson Nancy J | director | 12,866 0.0069% | $8.04 | $103,443 | -24.18% | |
| 2023-04-03 | Sale | Thackray Helen M. | Chief R&D Officer | 7,000 0.0037% | $8.29 | $58,030 | -18.28% | |
| 2023-02-01 | Sale | Stonehouse Jon P | President & CEO | 100,000 0.0523% | $10.38 | $1.04M | -31.84% | |
| 2022-12-15 | Sale | Stonehouse Jon P | President & CEO | 14,100 0.0079% | $10.90 | $153,690 | -30.43% | |
| 2022-12-15 | Sale | Gayer Charles K | Chief Commercial Officer | 6,100 0.0034% | $10.90 | $66,490 | -30.43% |
Insider Historical Profitability
| Hutson Nancy J | director | 86638 0.0414% | $887,173.12 | 3 | 4 | +118.24% |
| MILANO VINCENT | director | 66997 0.032% | $686,049.28 | 2 | 0 | +5.36% |
| HEGGIE THERESA | director | 52852 0.0253% | $541,204.48 | 1 | 1 | +118.24% |
| LEVIN ALAN G | director | 44951 0.0215% | $460,298.24 | 1 | 0 | |
| SANDERS MACHELLE | director | 27742 0.0133% | $284,078.08 | 0 | 2 | |
| McKee Amy E | director | 27831 0.0133% | $284,989.44 | 0 | 1 | |
| ASELAGE STEVE | director | 2500 0.0012% | $25,600.00 | 4 | 0 | +52.14% |
| BAKER FELIX | 10 percent owner | 4832285 2.3093% | $49.48M | 1 | 0 | +60.41% |
| Baker Brothers Life Sciences Capital (GP), LLC | 10 percent owner | 3831534 1.8311% | $39.23M | 3 | 3 | +289.09% |
| BAKER BROS. ADVISORS LP | 10 percent owner | 1551387 0.7414% | $15.89M | 11 | 3 | <0.0001% |
| Baker Biotech Capital (GP), LLC | 10 percent owner | 1522015 0.7274% | $15.59M | 3 | 3 | +289.09% |
| BVF PARTNERS L P/IL | Indirect Beneficial Owner | 1455900 0.6958% | $14.91M | 0 | 1 | |
| Stonehouse Jon P | President & CEO | 1127770 0.539% | $11.55M | 14 | 8 | +33.26% |
| GORDON CARL L | director | 1100000 0.5257% | $11.26M | 0 | 1 | |
| SHERRILL JOSEPH H JR | director | 492000 0.2351% | $5.04M | 5 | 0 | +141.01% |
| Gayer Charles K | Chief Commercial Officer | 307533 0.147% | $3.15M | 1 | 1 | |
| Barnes Alane P | Chief Legal Officer | 300762 0.1437% | $3.08M | 2 | 8 | +118.24% |
| Babu Yarlagadda S | Chief Discovery Officer | 298541 0.1427% | $3.06M | 1 | 14 | +118.24% |
| Thackray Helen M. | Chief R&D Officer | 272139 0.1301% | $2.79M | 1 | 3 | |
| Doyle Anthony | Chief Financial Officer | 266744 0.1275% | $2.73M | 3 | 1 | +77.54% |
| FEATHERINGILL WILLIAM W | director, 10 percent owner | 231538 0.1107% | $2.37M | 3 | 4 | <0.0001% |
| STAAB THOMAS R II | Senior Vice President and CFO | 125176 0.0598% | $1.28M | 0 | 46 | |
| 14159 capital (GP), LLC | 10 percent owner | 120828 0.0577% | $1.24M | 3 | 3 | +289.09% |
| Cohen Fred E | director | 119410 0.0571% | $1.22M | 0 | 1 | |
| Baker Bros. Capital (GP), LLC | 10 percent owner | 71997 0.0344% | $737,249.28 | 3 | 3 | +289.09% |
| BENNETT J CLAUDE | Chief Operating Officer | 65730 0.0314% | $673,075.20 | 2 | 5 | <0.0001% |
| BUGG CHARLES E | director | 62439 0.0298% | $639,375.36 | 0 | 3 | |
| Jensen Peder | director | 60000 0.0287% | $614,400.00 | 4 | 0 | +3.75% |
| Galson Steven K | director | 51551 0.0246% | $527,882.24 | 1 | 0 | |
| INGRAM ROBERT ALEXANDER | director | 48088 0.023% | $492,421.12 | 1 | 0 | +118.24% |
| MONTGOMERY JOHN A | director | 46785 0.0224% | $479,078.40 | 0 | 1 | |
| Sniecinski Megan | Chief Business Officer | 45000 0.0215% | $460,800.00 | 1 | 0 | +118.24% |
| Erck Stanley C | director | 40000 0.0191% | $409,600.00 | 1 | 0 | +454.8% |
| Sheridan William P | Chief Medical Officer | 37954 0.0181% | $388,648.96 | 1 | 16 | +240.53% |
| LEE KENNETH B JR | director | 24252 0.0116% | $248,340.48 | 1 | 2 | +118.24% |
| Baker / Tisch Capital (GP), LLC | 10 percent owner | 17241 0.0082% | $176,547.84 | 3 | 3 | +289.09% |
| Grant Stuart | SR VP & CFO | 14717 0.007% | $150,702.08 | 2 | 10 | +102.99% |
| McCullough David | VP | 13926 0.0067% | $142,602.24 | 0 | 4 | |
| Jones Michael L | Exec. Director, Finance - PAO | 10753 0.0051% | $110,110.72 | 0 | 3 | |
| SANDERS CHARLES A | director | 7000 0.0033% | $71,680.00 | 2 | 0 | <0.0001% |
| ALEXANDER W JAMES | SR. VP, Chief Medical Officer | 3659 0.0017% | $37,468.16 | 2 | 0 | <0.0001% |
| DARWIN MICHAEL A | Principal Accounting Officer | 3048 0.0015% | $31,211.52 | 2 | 2 | <0.0001% |
| HOROVITZ ZOLA P | director | 3000 0.0014% | $30,720.00 | 0 | 4 | |
| SEIDENBERG BETH C | director | 3000 0.0014% | $30,720.00 | 1 | 0 | <0.0001% |
| RIGGS RANDALL B | Senior VP Business Development | 1928 0.0009% | $19,742.72 | 2 | 1 | <0.0001% |
| Nugent Jonathan M | VP Corp Communications | 508 0.0002% | $5,201.92 | 2 | 1 | <0.0001% |
| Mills Mike | Principal Accounting Officer | 0 0% | $0 | 0 | 4 | |
| ABERCROMBIE GEORGE B | 0 0% | $0 | 2 | 8 | +230.41% | |
| Powell Lynne | Senior VP - CCO | 0 0% | $0 | 0 | 15 |
Historical Insider Profitability vs. Competitors
$66,492,695 | 135 | 27.65% | $2.02B | |
$193,151,375 | 134 | 8.18% | $1.98B | |
BioCryst Pharmaceuticals, Inc. (BCRX) | $20,297,544 | 73 | 103.06% | $2.14B |
$1,376,668 | 53 | 18.46% | $2.14B | |
$224,368,761 | 42 | 28.26% | $2.23B | |
$140,165,669 | 33 | 85.24% | $2.46B | |
$5,066,938 | 27 | 26.38% | $2.32B | |
$1,801,511 | 23 | 18.58% | $2.17B | |
$174,105,409 | 15 | 10.88% | $2.19B | |
$75,296,816 | 12 | 37.23% | $1.97B | |
$1,248,715 | 10 | 5.66% | $2.29B | |
$117,959,652 | 9 | -12.47% | $2.39B | |
$55,713,031 | 8 | -0.36% | $2.51B | |
$25,073,947 | 7 | -5.99% | $2.01B | |
$142,493,653 | 3 | 4.30% | $1.92B | |
$276,224 | 2 | -7.04% | $2.12B | |
$9,900,000 | 1 | -7.19% | $2B | |
$49,999,992 | 1 | 50.02% | $2.42B | |
$7,600,000 | 1 | -4.05% | $1.94B |
BCRX Institutional Investors: Active Positions
| Increased Positions | 122 | +42.51% | 10M | +6.12% |
| Decreased Positions | 114 | -39.72% | 15M | -8.53% |
| New Positions | 33 | New | 2M | New |
| Sold Out Positions | 32 | Sold Out | 2M | Sold Out |
| Total Postitions | 295 | +2.79% | 167M | -2.41% |
BCRX Ownership Change vs Market
Institutional Investor Ownership
| Blackrock, Inc. | $203,329.00 | 10.89% | 22.77M | +674,083 | +3.05% | 2025-03-31 |
| Vanguard Group Inc | $195,481.00 | 10.47% | 21.89M | +2M | +7.8% | 2024-12-31 |
| Avoro Capital Advisors Llc | $105,954.00 | 5.68% | 11.87M | 0 | 0% | 2024-12-31 |
| Kynam Capital Management, Lp | $81,132.00 | 4.35% | 9.09M | 0 | 0% | 2024-12-31 |
| Deerfield Management Company, L.P. (Series C) | $72,730.00 | 3.9% | 8.14M | +8,638 | +0.11% | 2024-12-31 |
| State Street Corp | $66,966.00 | 3.59% | 7.5M | -1M | -15.26% | 2024-12-31 |
| Alkeon Capital Management Llc | $63,348.00 | 3.39% | 7.09M | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $43,076.00 | 2.31% | 4.82M | -14,250 | -0.29% | 2024-12-31 |
| Nuveen Asset Management, Llc | $30,532.00 | 1.64% | 3.42M | -1M | -28.98% | 2024-12-31 |
| Fisher Asset Management, Llc | $28,421.00 | 1.52% | 3.18M | -155,445 | -4.66% | 2024-12-31 |